CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors.

Saved in:
Bibliographic Details
Title: CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors.
Authors: Zouggari N; Department of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Department of Molecular and Cellular Biology, Faculty of Sciences, University of Geneva, Geneva, Switzerland., Trugenberger C; Department of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Department of Molecular and Cellular Biology, Faculty of Sciences, University of Geneva, Geneva, Switzerland., Du Bois V; Department of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland., Wang W; Department of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland., Rossetti GG; Department of Molecular and Cellular Biology, Faculty of Sciences, University of Geneva, Geneva, Switzerland., Halazonetis TD; Department of Molecular and Cellular Biology, Faculty of Sciences, University of Geneva, Geneva, Switzerland., Labidi-Galy I; Department of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Source: Frontiers in oncology [Front Oncol] 2025 Nov 19; Vol. 15, pp. 1626301. Date of Electronic Publication: 2025 Nov 19 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2234-943X
DOI:10.3389/fonc.2025.1626301